COVID-19 Information

Edit Entry | Edit CV

Anna N. A. Tosteson, ScD

Title(s)
Interim Director and Professor of The Dartmouth Institute
Professor of Medicine
Professor of Community and Family Medicine
James J. Carroll 1948 Professor of Oncology

Additional Titles/Positions/Affiliations
Director, Comparative Effectiveness Research Program, The Dartmouth Institute for Health Policy and Clinical Practice
Associate Director for Population Sciences, Norris Cotton Cancer Center
Associate Director, SYNERGY, Dartmouth's Clinical and Translational Science Institute

Department(s)
The Dartmouth Institute
Medicine
Community and Family Medicine

Education
Biostatistics (Health Decision Sciences), Harvard University, ScD
Biostatistics, Harvard University, MS
Statistics & Biometry, Cornell University, BS

Programs
Norris Cotton Cancer Center
SYNERGY
The Dartmouth Institute for Health Policy and Clinical Practice

Contact Information

Dartmouth Medical School
HB 7505
One Medical Center Drive
Lebanon NH 03756

Office: WTRB 526, DHMC
Phone: 603-653-3568
Email: Anna.Tosteson@dartmouth.edu

Assistant: Christopher Jacobs
Asst. Phone: 603-653-0802
Asst. Email: Christopher.R.Jacobs@Dartmouth.EDU


Professional Interests

Dr. Anna Tosteson is a decision scientist and health services researcher who studies how the diffusion of innovations in health care are changing health, costs and quality of care. Through study of diverse data sources including registries, clinical and epidemiological studies, and administrative claims data, she seeks insights into the long-term clinical and economic effects of alternative approaches to health care delivery with a focus on cancer screening, musculoskeletal disease, and women’s health.

Grant Information

Promoting follow-up of abnormal cancer screening tests using population-based systems to support stepped care multilevel intervention. (NCI: U01CA225451 )

Risk-based breast cancer screening and surveillance in community practice. (NCI, P01CA154292)

Courses Taught

PH 119/121; QBS 140 Decision and Cost-Effectiveness Analysis


Selected Publications

 

Prioritizing Measures That Matter Within a Person-Centered Oncology Learning Health System.
Van Citters AD, Kennedy AM, Kirkland KB, Dragnev KH, Leach SD, Buus-Frank ME, Malcolm EF, Holthoff MM, Holmes AB, Nelson EC, Reeves SA, Tosteson ANA, Promise Partnership Delphi Panel .
JNCI Cancer Spectr. 2022 May 2;6(3) pii: pkac037. doi: 10.1093/jncics/pkac037.
PMID: 35736219

Decision quality and regret with treatment decisions in women with breast cancer: Pre-operative breast MRI and breast density.
Wernli KJ, Smith RE, Henderson LM, Zhao W, Durham DD, Schifferdecker K, Kaplan C, Buist DSM, Kerlikowske K, Miglioretti DL, Onega T, Alsheik NH, Sprague BL, Jackson-Nefertiti G, Budesky J, Johnson D, Tosteson ANA
Breast Cancer Res Treat. 2022 Jun 20; doi: 10.1007/s10549-022-06648-7. Epub 2022 Jun 20.
PMID: 35723793

Association of Screening With Digital Breast Tomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer.
Kerlikowske K, Su YR, Sprague BL, Tosteson ANA, Buist DSM, Onega T, Henderson LM, Alsheik N, Bissell MCS, O'Meara ES, Lee CI, Miglioretti DL
JAMA. 2022 Jun 14;327(22):2220-2230. doi: 10.1001/jama.2022.7672.
PMID: 35699706

Natural Language Processing to Identify Abnormal Breast, Lung, and Cervical Cancer Screening Test Results from Unstructured Reports to Support Timely Follow-up.
Diamond CJ, Laurentiev J, Yang J, Wint A, Harris KA, Dang TH, Mecker A, Carpenter EB, Tosteson AN, Wright A, Haas JS, Atlas SJ, Zhou L
Stud Health Technol Inform. 2022 Jun 6;290:433-437. doi: 10.3233/SHTI220112.
PMID: 35673051

Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
Brooks GA, Tapp S, Daly AT, Busam JA, Tosteson ANA
Clin Colorectal Cancer. 2022 May 11; pii: S1533-0028(22)00055-X. doi: 10.1016/j.clcc.2022.05.001. Epub 2022 May 11.
PMID: 35668003

Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: A decision analysis approach.
Gilstrap L, Zipkin RJ, Barnes JA, King A, O'Malley AJ, Gaziano TA, Tosteson ANA
Am Heart J. 2022 Aug;250:23-28. doi: 10.1016/j.ahj.2022.04.007. Epub 2022 May 4.
PMID: 35525261

Factors Influencing Telemedicine Use at a Northern New England Cancer Center During the COVID-19 Pandemic.
Mackwood MB, Tosteson TD, Alford-Teaster JA, Curtis KM, Lowry ML, Snide JA, Zhao W, Tosteson ANA
JCO Oncol Pract. 2022 Apr 21;:OP2100750. doi: 10.1200/OP.21.00750. Epub 2022 Apr 21.
PMID: 35446680

Breast Density Knowledge in a Screening Mammography Population Exposed to Density Notification.
Smith RE, Sprague B, Henderson LM, Kerlikowske K, Miglioretti DL, Buist DSM, Wernli KJ, Onega T, Schifferdecker K, Jackson-Nefertiti G, Johnson D, Budesky J, Tosteson ANA
J Am Coll Radiol. 2022 May;19(5):615-624. doi: 10.1016/j.jacr.2022.02.025. Epub 2022 Mar 24.
PMID: 35341697

Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography.
Ho TH, Bissell MCS, Kerlikowske K, Hubbard RA, Sprague BL, Lee CI, Tice JA, Tosteson ANA, Miglioretti DL
JAMA Netw Open. 2022 Mar 1;5(3):e222440. doi: 10.1001/jamanetworkopen.2022.2440. Epub 2022 Mar 1.
PMID: 35333365

Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
Lowry KP, Geuzinge HA, Stout NK, Alagoz O, Hampton J, Kerlikowske K, de Koning HJ, Miglioretti DL, van Ravesteyn NT, Schechter C, Sprague BL, Tosteson ANA, Trentham-Dietz A, Weaver D, Yaffe MJ, Yeh JM, Couch FJ, Hu C, Kraft P, Polley EC, Mandelblatt JS, Kurian AW, Robson ME, Breast Working Group of the Cancer Intervention and Surveillance Modeling Network (CISNET), in collaboration with the Breast Cancer Surveillance Consortium (BCSC), and the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium.
JAMA Oncol. 2022 Apr 1;8(4):587-596. doi: 10.1001/jamaoncol.2021.6204.
PMID: 35175286

View more publications on PubMed